The independent source for health policy research, polling, and news.
181-200 of 704 results
Gov. Gavin Newsom proposed spending $100 million to make insulin affordable to millions of people with diabetes under a new state generic drug label, CalRx. But state officials haven鈥檛 said how much the insulin will cost patients or how the state will deal with distribution and other challenges.
Stemming gun violence is back on the legislative agenda following three mass shootings in less than a month, but it鈥檚 hard to predict success when so many previous efforts have failed. Meanwhile, lawmakers must soon decide if they will extend current premium subsidies for those buying health insurance under the Affordable Care Act, and the Biden administration acts, belatedly, on Medicare premiums. Margot Sanger-Katz of the New York Times, Sandhya Raman of CQ Roll Call, and Rachel Cohrs of Stat News join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN鈥檚 Michelle Andrews, who reported and wrote the latest KHN-NPR 鈥淏ill of the Month鈥 episode about a too-common problem: denial of no-cost preventive care for a colonoscopy under the Affordable Care Act.
Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications is no bargain after prices go up.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
A diabetes diagnosis is not always related to a person鈥檚 weight or overall health, especially for those with Type 1 diabetes, who are dependent on insulin treatment for life.
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare鈥檚 coverage decision for the controversial Alzheimer鈥檚 disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
President Joe Biden welcomed former President Barack Obama back to the White House this week to announce a new policy for the Affordable Care Act that would make subsidies available to more families with unaffordable employer coverage. Meanwhile, Congress struggled to find a compromise for continued federal funding of covid-19 vaccines, testing, and treatments. Tami Luhby of CNN, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more.
The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.
A 杨贵妃传媒視頻 Health News database tracks campaign donations from drugmakers over the past 10 years.
Gov. Gavin Newsom has launched several initiatives to cut rising drug prices, but the savings haven鈥檛 been as monumental as he promised. And his plan to have California make its own generic drugs hasn鈥檛 gotten off the ground.
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer鈥檚 drug that scientists say has not been proven to work.
A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer鈥檚 drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more.
Sen. Joe Manchin (D-W.Va.) dealt a blow to congressional efforts to pass President Joe Biden鈥檚 domestic agenda bill, forcing Democrats to regroup starting in 2022. Meanwhile, the omicron covid variant spreads rapidly in the U.S., threatening the stability of the nation鈥檚 health care system. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these issues and more, plus a look back at the year in health policy. Also this week, Rovner interviews Ceci Connolly, president and CEO of the Alliance of Community Health Plans.
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals 鈥 loudly 鈥 that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more.
President Joe Biden鈥檚 social spending budget is on its way to the U.S. Senate, where Democratic leaders are (optimistically) hoping to complete work by the end of the year. Meanwhile, covid is surging again in parts of the country, along with the political divides it continues to cause. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins School of Public Health, and Mary Agnes Carey of KHN join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner previews next week鈥檚 Supreme Court abortion oral arguments with Florida State University law professor Mary Ziegler.
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it鈥檚 鈥渁 far cry鈥 from what other nations do to rein in drug prices, and polls show most voters demand more protection.
More than 1,000 independent rural pharmacies have closed since 2003, leaving 630 communities with no retail drugstore. As 41 million people stuck in pharmacy deserts make do, the remaining drugstores struggle to survive.
Kids who need a hormone-blocking drug to delay puberty have lost an off-label option. The nearly identical drug the company still sells costs eight times more.
漏 2026 KFF